$ImmunoGen_老虎社区_美港股上老虎 - 老虎社区

1
评论
收藏

牛唐
2023-12-01

$ImmunoGen(IMGN)$ 提前布局。

医药板块速评（2023.11.17)

1、生物医药板块接连突破，哪些优质医药股还有配置机会？ $SPDR S&P Biotech ETF(XBI)$ 2、减肥药大年，还有哪些GLP-1药企有机会？ $礼来(LLY)$ $诺和诺德(NVO)$ 3、 $ImmunoGen(IMGN)$ 大单看涨期权，是否有被收购机会？ $再鼎医药(ZLAB)$

医药板块速评（2023.11.17)

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

1

举报

评论

推荐
最新

empty

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

老虎社区侵权投诉指引

中国互联网举报中心·北京互联网举报中心

网络谣言曝光台·扫黄打非举报中心

网络110报警服务

© 2018-2024 老虎社区版权所有

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

qrcode

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":247405149925672,"tweetId":"247405149925672","gmtCreate":1701439514872,"gmtModify":1701439515917,"author":{"id":3452938437060827,"authorId":3452938437060827,"authorIdStr":"3452938437060827","name":"牛唐","avatar":"https://static.tigerbbs.com/de2e2f2e2676bc8463b050f4e3ff17d2","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6127,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><a target=\"_blank\" href=\"https://laohu8.com/S/IMGN\">$ImmunoGen(IMGN)$ </a>提前布局。<br></body></html>","htmlText":"<html><head></head><body><a target=\"_blank\" href=\"https://laohu8.com/S/IMGN\">$ImmunoGen(IMGN)$ </a>提前布局。<br></body></html>","text":"$ImmunoGen(IMGN)$ 提前布局。","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/247405149925672","repostId":243588194050112,"repostType":1,"repost":{"magic":2,"id":243588194050112,"tweetId":"243588194050112","gmtCreate":1700489577857,"gmtModify":1700489579695,"author":{"id":3452938437060827,"authorId":3452938437060827,"authorIdStr":"3452938437060827","name":"牛唐","avatar":"https://static.tigerbbs.com/de2e2f2e2676bc8463b050f4e3ff17d2","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6127,"starInvestorFlag":false},"themes":[{"themeId":"5bba0d04dd2e483aa6d779e7d44fac92","categoryId":"d316d8bd4a714fab9ea15fd7157c45e7","name":"药明合联涨超30%，港股IPO“新宠”继续持有？","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":5bba0d04dd2e483aa6d779e7d44fac92}&rnconfig={\"headerBarHidden\": true}","description":"今日药明合联首挂上市，公告显示公司发行1.78亿股股份，每股定价20.6港元，截至11月17日10: 55，盘中涨超36%，总市值达331亿港元。身处XDC热门赛道，药明合联昨日暗盘最高超涨20%，今日上市开盘继续超涨30%！药明合联的上市可以给港股打新市场助力吗？你会选择继续持有吗？","image":"https://static.tigerbbs.com/32905b448305f5d4040d4fd247484c7b"}],"images":[],"coverImages":[],"title":"医药板块速评（2023.11.17)","html":"<html><head></head><body><p style=\"text-align: start;\">1、生物医药板块接连突破， 哪些优质医药股还有配置机会？ <a href=\"https://laohu8.com/S/XBI\">$SPDR S&amp;P Biotech ETF(XBI)$</a> </p>\n<p style=\"text-align: start;\">2、减肥药大年，还有哪些GLP-1药企有机会？ <a href=\"https://laohu8.com/S/LLY\">$礼来(LLY)$</a> <a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$</a> </p>\n<p style=\"text-align: start;\">3、 <a href=\"https://laohu8.com/S/IMGN\">$ImmunoGen(IMGN)$</a> 大单看涨期权，是否有被收购机会？</p>\n<p> <a href=\"https://laohu8.com/S/ZLAB\">$再鼎医药(ZLAB)$</a> </p></body></html>","htmlText":"<html><head></head><body><p style=\"text-align: start;\">1、生物医药板块接连突破， 哪些优质医药股还有配置机会？ <a href=\"https://laohu8.com/S/XBI\">$SPDR S&amp;P Biotech ETF(XBI)$</a> </p>\n<p style=\"text-align: start;\">2、减肥药大年，还有哪些GLP-1药企有机会？ <a href=\"https://laohu8.com/S/LLY\">$礼来(LLY)$</a> <a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$</a> </p>\n<p style=\"text-align: start;\">3、 <a href=\"https://laohu8.com/S/IMGN\">$ImmunoGen(IMGN)$</a> 大单看涨期权，是否有被收购机会？</p>\n<p> <a href=\"https://laohu8.com/S/ZLAB\">$再鼎医药(ZLAB)$</a> </p></body></html>","text":"1、生物医药板块接连突破， 哪些优质医药股还有配置机会？ $SPDR S&P Biotech ETF(XBI)$ 2、减肥药大年，还有哪些GLP-1药企有机会？ $礼来(LLY)$ $诺和诺德(NVO)$ 3、 $ImmunoGen(IMGN)$ 大单看涨期权，是否有被收购机会？ $再鼎医药(ZLAB)$","highlighted":1,"essential":1,"paper":2,"link":"https://laohu8.com/post/243588194050112","repostId":0,"isVote":1,"tweetType":1,"commentLimit":10,"symbols":["IMGN","ZLAB","LLY","NVO","XBI","09688"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":true,"length":202,"xxTargetLangEnum":"ZH_CN"},"isVote":1,"tweetType":1,"viewCount":1990,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["IMGN"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":26,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}